TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You …

TG Therapeutics (TGTX) closed the most recent trading day at $18.43, moving -0.27% from the previous trading session. This move lagged the S&P 500's daily gain of 1.29%. Elsewhere, the …

27%
OFF

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You …

2 weeks from now

TG Therapeutics (TGTX) closed the most recent trading day at $18.43, moving -0.27% from the previous trading session. This move lagged the S&P 500's daily gain of 1.29%. Elsewhere, the …

yahoo.com

46%
OFF

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You …

2 weeks from now

Apr 6, 2023 · TG Therapeutics (TGTX) closed at $15.48 in the latest trading session, marking a -1.46% move from the prior day.

yahoo.com

41%
OFF

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You …

2 weeks from now

Mar 24, 2023 · In the latest trading session, TG Therapeutics (TGTX) closed at $14.70, marking a -1.41% move from the previous day.

yahoo.com

48%
OFF

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You

2 weeks from now

Mar 30, 2023 · TG Therapeutics (TGTX) closed the most recent trading day at $14.63, moving -1.48% from the previous trading session. This change lagged the S&P 500's daily gain of 0.57%.

nasdaq.com

46%
OFF

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You

2 weeks from now

Apr 6, 2023 · In the latest trading session, TG Therapeutics (TGTX) closed at $15.48, marking a -1.46% move from the previous day. This change lagged the S&P 500's daily gain of 0.36%. At …

nasdaq.com

9%
OFF

TG Therapeutics (NASDAQ:TGTX) Shares Down 2.9% - Time To …

2 weeks from now

Jan 6, 2025 · Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) traded down 2.9% on Monday . The stock traded as low as $29.01 and last traded at $29.19. 195,725 …

marketbeat.com

$28.00
OFF

TG Therapeutics (NASDAQ:TGTX) Rating Increased To Hold At

2 weeks from now

Jan 8, 2025 · NASDAQ TGTX remained flat at $28.00 on Tuesday. The company's stock had a trading volume of 2,930,795 shares, compared to its average volume of 2,870,394. The firm …

marketbeat.com

61%
OFF

TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You …

2 weeks from now

Jan 12, 2023 · TG Therapeutics (TGTX) closed at $13.20 in the latest trading session, marking a +0.61% move from the prior day.

zacks.com

61%
OFF

TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You

2 weeks from now

Jan 12, 2023 · In the latest trading session, TG Therapeutics (TGTX) closed at $13.20, marking a +0.61% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.34%. …

nasdaq.com

$27.67
OFF

TG Therapeutics (NASDAQ:TGTX) Shares Gap Up - Time To Buy?

2 weeks from now

20 hours ago · Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $27.67, but …

marketbeat.com

48%
OFF

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You …

2 weeks from now

Mar 30, 2023 · TG Therapeutics (TGTX) closed the most recent trading day at $14.63, moving -1.48% from the previous trading session. This change lagged the S&P 500's daily gain of 0.57%.

yahoo.com

9%
OFF

Why TGTX Stock Is Rallying Today - Insider Monkey

2 weeks from now

15 hours ago · The shares of drug maker TG Therapeutics (TGTX) are climbing 9% today after the firm preannounced higher-than-expected 2024 revenue from its multiple sclerosis drug, …

insidermonkey.com

0%
OFF

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought By

2 weeks from now

4 days ago · JPMorgan Chase & Co. raised its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 60.0% during the third quarter, according to its most recent filing with the …

marketbeat.com

$10.00
OFF

Bank Of America Securities Reaffirms Their Sell Rating On TG ...

2 weeks from now

1 day ago · Bank of America Securities analyst Alec Stranahan maintained a Sell rating on TG Therapeutics (TGTX – Research Report) today and set a price target of $10.00.

businessinsider.com

7%
OFF

TG Therapeutics’ Stock Rockets After Blowout Earnings

2 weeks from now

Nov 1, 2023 · The stock TGTX shot up 26.7% in morning trading, which puts it on track for the biggest one-day gain since it ran up 63.4% on Nov. 10, 2022.

marketwatch.com

9%
OFF

Why TGTX Stock Is Rallying Today - Yahoo Finance

2 weeks from now

15 hours ago · The shares of drug maker TG Therapeutics (TGTX) are climbing 9% today after the firm preannounced higher-than-expected 2024 revenue from its multiple sclerosis drug, …

yahoo.com

FAQs about TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You … Coupon?

What happened to TG Therapeutics (tgtx)?

TG Therapeutics (TGTX) closed the most recent trading day at $18.43, moving -0.27% from the previous trading session. This move lagged the S&P 500's daily gain of 1.29%. Elsewhere, the Dow gained 0.78%, while the tech-heavy Nasdaq lost 4.94%. ...

Why are TG Therapeutics (tgtx) shares climbing 9% today?

The shares of drug maker TG Therapeutics (TGTX) are climbing 9% today after the firm preannounced higher-than-expected 2024 revenue from its multiple sclerosis drug, Briumvi. Briumvi's 2024 Revenue Exceeded TG's Guidance The company estimated today that its 2024 revenue from the MS treatment had come in at $310 million. ...

What does tgtx stand for?

TG Therapeutics (TGTX) Company Description: TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. ...

Is TG Therapeutics (TG) a leader in the medical - products industry?

TG Therapeutics is holding a Zacks Rank of #3 (Hold) right now. The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 150, which puts it in the bottom 41% of all 250+ industries. ...

How much revenue will TG Therapeutics generate this year?

According to TG Therapeutics (NASDAQ: TGTX), the intravenously delivered treatment is expected to generate about $525M in net product revenue this year from the U.S., expanding its global revenue to roughly $540M. ...

How did TG's trading volume compare to the full-day average?

Trading volume swelled to 24 million shares, compared with the full-day average over the past 30 days of about 4.3 million shares. For the quarter to Sept. 30, TG swung to net income of $113.9 million, or 73 cents a share, from a loss of $35.8 million, or 26 cents a share, in the same period a year ago. ...